ERBB2 and breast carcinoma: Based on the results of DestinyBreast01, T-DXd has been approved by the Food and Drug Administration (FDA) for the treatment of patients with metastatic HER2-positive breast cancer after two prior lines of therapy [37], paying attention to potentially life-threatening interstitial lung disease as specific drug-related toxicity.